Endocrine therapy alone vs chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: A retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology)

Basit Öğe Kaydı
dc.authoridGöksel, Gamze/0000-0002-7991-0036
dc.authoridYücel, Şebnem/0000-0001-6235-7927
dc.authoridDEMIRCI, UMUT/0000-0002-4833-6721
dc.authorwosidGöksel, Gamze/HHC-6548-2022
dc.authorwosidGeredeli, Caglayan/AAN-4122-2020
dc.authorwosidDogu, Gamze Gokoz/A-9815-2010
dc.authorwosidYücel, Şebnem/AAY-6737-2021
dc.authorwosidunal, olcun umit/IST-6684-2023
dc.contributor.authorInal, A.
dc.contributor.authorAkman, T.
dc.contributor.authorYaman, S.
dc.contributor.authorOzturk, S. Demir
dc.contributor.authorGeredeli, C.
dc.contributor.authorBilici, M.
dc.contributor.authorInanc, M.
dc.date.accessioned2024-08-04T20:37:41Z
dc.date.available2024-08-04T20:37:41Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: The extra benefit of adding chemotherapy to effective endocrine therapy (ET) has not been clearly or consistently identified in patients older than 70 years with estrogen receptor (ER) positive and node positive breast cancer. The aim of this study was to evaluate the efficacy of adjuvant ET vs chemotherapy plus endocrine therapies (Chemo/ET) in such patients. Methods: In this retrospective multicenter study 191 patients >= 70 years with operated hormone receptor positive breast cancer, who were administered adjuvant ET or Chemo/ET were assessed. Results: The median patient follow-up time was 29.0 months (range 1-252). Therefore disease free survival (DFS) and overall survival (OS) analysis was limited, due to the rather short median follow-up, and only 30-month cumulative percentages are reported herein. The 30-month DFS rates were 50.0% in the ET arm and 49.0% in the Chemo/ET arm (p=0.79). The 30-month OS rates were 86% in the ET arm and 96.0% in the Chemo/ET arm (p=0.08). Cox proportional hazard model showed that only surgery was independent prognostic factor for survival (p=0.047), while tumor size showed a strong trend for statistical significance (p=0.051). Conclusion: The addition of chemotherapy to endocrine therapy in older patients has no significant impact on DFS and OS.en_US
dc.identifier.endpage69en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1en_US
dc.identifier.pmid23613390en_US
dc.identifier.scopus2-s2.0-84879018143en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage64en_US
dc.identifier.urihttps://hdl.handle.net/11616/96097
dc.identifier.volume18en_US
dc.identifier.wosWOS:000322750600008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectadjuvant treatmenten_US
dc.subjectbreast canceren_US
dc.subjectchemotherapyen_US
dc.subjectelderly patientsen_US
dc.subjecthormonal therapyen_US
dc.titleEndocrine therapy alone vs chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: A retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu